000141907 001__ 141907
000141907 005__ 20240229105135.0
000141907 0247_ $$2doi$$a10.1093/ajcn/nqy196
000141907 0247_ $$2pmid$$apmid:30475957
000141907 0247_ $$2ISSN$$a0002-9165
000141907 0247_ $$2ISSN$$a0095-9871
000141907 0247_ $$2ISSN$$a1938-3207
000141907 0247_ $$2ISSN$$a1938-3215
000141907 0247_ $$2altmetric$$aaltmetric:51599621
000141907 037__ $$aDKFZ-2018-02164
000141907 041__ $$aeng
000141907 082__ $$a570
000141907 1001_ $$0P:(DE-He78)ceb74219d144ab5760a228e71440c5ca$$aSchübel, Ruth$$b0$$eFirst author$$udkfz
000141907 245__ $$aEffects of intermittent and continuous calorie restriction on body weight and metabolism over 50 wk: a randomized controlled trial.
000141907 260__ $$aOxford$$bOxford University Press$$c2018
000141907 3367_ $$2DRIVER$$aarticle
000141907 3367_ $$2DataCite$$aOutput Types/Journal article
000141907 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1544448920_27697
000141907 3367_ $$2BibTeX$$aARTICLE
000141907 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141907 3367_ $$00$$2EndNote$$aJournal Article
000141907 520__ $$aAlthough preliminary evidence suggests that intermittent calorie restriction (ICR) exerts stronger effects on metabolic parameters, which may link obesity and major chronic diseases, compared with continuous calorie restriction (CCR), there is a lack of well-powered intervention studies.We conducted a randomized controlled trial to test whether ICR, operationalized as the '5:2 diet,' has stronger effects on adipose tissue gene expression, anthropometric and body composition measures, and circulating metabolic biomarkers than CCR and a control regimen.One hundred and fifty overweight and obese nonsmokers [body mass index (kg/m2) ≥25 to <40, 50% women], aged 35-65 y, were randomly assigned to an ICR group (5 d without energy restriction and 2 d with 75% energy deficit, net weekly energy deficit ∼20%), a CCR group (daily energy deficit ∼20%), or a control group (no advice to restrict energy) and participated in a 12-wk intervention phase, a 12-wk maintenance phase, and a 26-wk follow-up phase.Loge relative weight change over the intervention phase was -7.1% ± 0.7% (mean ± SEM) with ICR, -5.2% ± 0.6% with CCR, and -3.3% ± 0.6% with the control regimen (Poverall < 0.001, PICR vs. CCR = 0.053). Despite slightly greater weight loss with ICR than with CCR, there were no significant differences between the groups in the expression of 82 preselected genes in adipose tissue implicated in pathways linking obesity to chronic diseases. At the final follow-up assessment (week 50), weight loss was -5.2% ± 1.2% with ICR, -4.9% ± 1.1% with CCR, and -1.7% ± 0.8% with the control regimen (Poverall = 0.01, PICR vs. CCR = 0.89). These effects were paralleled by proportional changes in visceral and subcutaneous adipose tissue volumes. There were no significant differences between ICR and CCR regarding various circulating metabolic biomarkers.Our results on the effects of the '5:2 diet' indicate that ICR may be equivalent but not superior to CCR for weight reduction and prevention of metabolic diseases. This trial was registered at clinicaltrials.gov as NCT02449148.
000141907 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141907 588__ $$aDataset connected to CrossRef, PubMed,
000141907 7001_ $$0P:(DE-HGF)0$$aNattenmüller, Johanna$$b1
000141907 7001_ $$aSookthai, Disorn$$b2
000141907 7001_ $$0P:(DE-He78)95cbb002ef4aaccc0a2fc6b596110f1a$$aNonnenmacher, Tobias$$b3$$udkfz
000141907 7001_ $$0P:(DE-HGF)0$$aGraf, Mirja E$$b4
000141907 7001_ $$aRiedl, Lena$$b5
000141907 7001_ $$aSchlett, Christopher L$$b6
000141907 7001_ $$avon Stackelberg, Oyunbileg$$b7
000141907 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron Scot$$b8$$udkfz
000141907 7001_ $$aNabers, Diana$$b9
000141907 7001_ $$aKirsten, Romy$$b10
000141907 7001_ $$aKratz, Mario$$b11
000141907 7001_ $$aKauczor, Hans-Ulrich$$b12
000141907 7001_ $$aUlrich, Cornelia M$$b13
000141907 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b14$$udkfz
000141907 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b15$$eLast author$$udkfz
000141907 773__ $$0PERI:(DE-600)1496439-9$$a10.1093/ajcn/nqy196$$gVol. 108, no. 5, p. 933 - 945$$n5$$p933 - 945$$tThe American journal of clinical nutrition$$v108$$x1938-3207$$y2018
000141907 909CO $$ooai:inrepo02.dkfz.de:141907$$pVDB
000141907 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ceb74219d144ab5760a228e71440c5ca$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141907 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141907 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)95cbb002ef4aaccc0a2fc6b596110f1a$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141907 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000141907 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141907 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000141907 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000141907 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141907 9141_ $$y2018
000141907 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J CLIN NUTR : 2017
000141907 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141907 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141907 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141907 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141907 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141907 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141907 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141907 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141907 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141907 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141907 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141907 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bAM J CLIN NUTR : 2017
000141907 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000141907 980__ $$ajournal
000141907 980__ $$aVDB
000141907 980__ $$aI:(DE-He78)C020-20160331
000141907 980__ $$aUNRESTRICTED